Vexim
Vexim, set up in 2006 as a spin-off from Teknimed, a French leader in orthopedic cements, specializes in minimally-invasive solutions for treatment of the causes and consequences of vertebral damage. It has notably developed the SpineJack® – a system for controlled anatomical repair of vertebral compression fractures (VCF). The market for VCF is estimated at $1 billion, with over 200,000 cases per year and growing at 20% a year.
Truffle initially invested in Vexim in 2006. Since then, Vexim has successfully treated hundreds of patients, obtained the CE mark for the SpineJack and secured an exclusive distribution agreement with Stryker, a global leader in medical technology. Vexim was listed on Alternext in May 2012 (ALVXM).
Truffle Capital board members: Dr. Philippe Pouletty
10 avril 2012 – Présentation de Vexim, spécialisée dans la chirurgie innovante du dos